`
`Paper No. ___
`Filed: March 26, 2018
`
`
`
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`—————————————————
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`—————————————————
`
`APPLE INC.,
`Petitioner,
`
`v.
`
`CALIFORNIA INSTITUTE OF TECHNOLOGY,
`Patent Owner.
`
`—————————————————
`
`Case IPR2017-00210
`Patents 7,116,710
`
`—————————————————
`
`PATENT OWNER’S REPLY IN SUPPORT OF MOTION TO EXCLUDE
`
`
`
`
`
`
`
`
`
`Cases IPR2017-00210
`Patents 7,116,710
`
`I.
`
`INTRODUCTION
`
`The Board should exclude new evidence in support of arguments raised for
`
`the first time in Petitioner’s Reply, including new attorney-generated graphs, data,
`
`theories of unpatentability, witness testimony and inexcusable failure to address
`
`reasonable expectation of success (“REOS”). Petitioner’s argument that the
`
`conclusory assertion that reengineering the Divsalar code is “trivial” shows a
`
`REOS was not presented in the petition and is wrong as a matter of law and fact.
`
`II. ARGUMENT
`
`A. The new arguments were not a part of the petition
`
`Evidence in support of Petitioner’s arguments never advanced in the petition
`
`should be excluded under FRE 401-403, including EXS1044-1049, 1057-1061,
`
`1065, and 1068. For example, Petitioner now claims that the conclusory assertion
`
`that the proposed modification is “trivial” addressed REOS. Opp. 4. But the
`
`“triviality” argument in the petition is clearly labeled as one regarding motivation
`
`to combine, not REOS (Pet. 44-45), and this is merely a post hac attempt to cure a
`
`deficient petition. Moreover, relative complexity of executing a modification
`
`simply does not speak to whether it would be conducted in the first place or
`
`expected to be successful. And besides elements being capable of combination,
`
`there must also be an expectation “that the combination would have worked for its
`
`intended purpose.” DePuy Spine, Inc. v. Medtronic Sofamor Danek, Inc., 567 F.3d
`
`-1-
`
`
`
`Cases IPR2017-00210
`Patents 7,116,710
`
`1314, 1326 (Fed. Cir. 2009). The petition made no showing that its proposed
`
`modification would have been expected to function, let alone improve codes,
`
`which cannot be cured in Reply with unreliable and misleading evidence that
`
`Caltech is not permitted to rebut with its own evidence.
`
`Further, Petitioner is simply wrong that its proposed modification was
`
`“trivial.” Frey, the only art reference that discloses irregular repetition of
`
`information bits, explicitly states that “[f]inding a good [irregular] profile is not
`
`trivial,” and depends on parameters such as “the permuter and the distortion
`
`measure” (EX1002, 5), neither of which Frey discloses. See EX2004 ¶¶95, 103.
`
`Petitioner also concedes that the field of error-correction codes was unpredictable
`
`(Reply 9), and yet “[u]npredictability of results equates more with nonobviousness
`
`rather than obviousness.” Honeywell Int’l, Inc. v. Mexichem Amanco Holding S.A.,
`
`865 F.3d 1348, 1356 (Fed. Cir. 2017).
`
`Petitioner also contends that it “is entitled to respond” to Caltech’s
`
`arguments in the POR. Opp. 5-6. But petitioner misses the point—critical aspects
`
`of an obviousness inquiry must be addressed in the petition. Fed. Register Vol. 77
`
`No. 157 at 48767 (identifying improper Reply). Attempting to fill an identified
`
`void in the petition materials is not a legitimate Reply material. Presenting an
`
`entirely new modification to an RA code because the original modification has
`
`been rebutted is not legitimate Reply material. Such content is more prejudicial
`
`-2-
`
`
`
`Cases IPR2017-00210
`Patents 7,116,710
`
`than probative as Caltech has no meaningful opportunity to respond.
`
`B. Other Divsalar-related exhibits should be excluded
`
`Petitioner claims EXS1057 and 1058 rebut Dr. Divsalar’s testimony. But
`
`Dr. Divsalar’s testimony that irregular repetition would add complexity with no
`
`expected benefit (or even functionality) remains unrebutted. EX2031 ¶¶33-36.
`
`Petitioner’s pivot from a modified code with a rate of 1/3 to a new modification
`
`with a much slower rate of 1/5 underscores, not rebuts, Dr. Divsalar’s testimony.
`
`Petitioner claims Exhibit 1061 impeaches Dr. Divsalar’s testimony that IRA
`
`codes “are not a subset of the RA codes described in [Divsalar].” Opp. 6-7. First,
`
`this was not an argument raised in the Reply. Second, the argument is nonsensical
`
`as Exhibit 1061 (not prior art) is not reflective of a POSA at the time and, at any
`
`rate, is entirely consistent with Dr. Divsalar’s testimony.
`
`C. Cross-examination of witnesses does not cure Caltech’s prejudice
`
`Contrary to Federal Circuit guidance, Petitioner argues that prejudice to
`
`Caltech regarding EXS1044-1049, 1032-1034, 1037, 1057-1061, 1062, 1064,
`
`1065, and 1068 could be cured by post reply cross-examination (and presumably
`
`observations on cross). Opp. 8-9, 12. But observations on cross-examination are
`
`not “a substitute for the opportunity to present arguments and evidence.” In re
`
`Nuvasive, Inc., 841 F.3d 966, 973 (Fed. Cir. 2016). And Caltech will have no
`
`opportunity to submit its own evidence to rebut Petitioner’s new belated evidence.
`
`-3-
`
`
`
`Cases IPR2017-00210
`Patents 7,116,710
`
`
`Moreover, Petitioner does not explain how its own improper questioning of
`
`Caltech’s witnesses (EX1062, 1064) would be cured by cross-examination of its
`
`own declarants. And Caltech objected to EX1074 for violating the Board’s
`
`prohibition on including substantive argument and the exhibit should be excluded
`
`under FRE 401-403. See Paper 59 (due after motion to exclude).
`
`With particular regard to Dr. Frey, Petitioner does not dispute that he did not
`
`consider Dr. Davis’s cross-examination. Cross-examination of Dr. Frey would not
`
`cure his failure to consider the full scope of Dr. Davis’s testimony in the first place.
`
`As to the Allerton witnesses and the supplemental information, Caltech
`
`responded to the petition’s assertion that Frey was published on March 20. Caltech
`
`relied on the Board’s guidance that worries about Petitioner pushing an earlier
`
`publication date were mere “speculat[ion]” and therefore premature. Paper 42, 3-
`
`4. Petitions require more than bare notice pleading, and “on or before March 20”
`
`is simply not adequate to apprise Caltech of intent to use an earlier date, let alone
`
`what that date might be. Moreover, with regard to antedating, only the last date of
`
`a range of dates is considered. See Oka v. Youssefyeh, 849 F.2d 581, 584 (Fed. Cir.
`
`1988). No February date was asserted in the petition, and Caltech will have no
`
`opportunity to present its own evidence to rebut the new publication theory.
`
`D. Dr. Davis’s unavailability remains suspect
`
`Petitioner falsely claims Caltech disputes the authenticity of Dr. Davis’s
`
`-4-
`
`
`
`Cases IPR2017-00210
`Patents 7,116,710
`
`Fulbright scholarship. Opp. 12. Rather, Petitioner’s assertion of Dr. Davis’
`
`unavailability strains credulity considering that (1) Dr. Davis knew of his Fulbright
`
`responsibilities by at least February 2017, a year before the Reply materials were
`
`due; (2) Dr. Frey asserts that his declaration efforts only took a few hours
`
`(EX1065, ¶¶45-55); (3) Dr. Davis testified that Petitioner’s counsel conducts most
`
`of the drafting of witness testimony (EX2066 12:6-7); and (4) Dr. Davis remains
`
`available for deposition in the U.S. (EX1073 ¶3).
`
`E.
`
`Exhibit 1067 should not be considered in a vacuum
`
`Petitioner provides no response to Caltech’s showing that, per FRE 106,
`
`Exhibit 1067 should only be considered in the context of the relevant district court
`
`record. Mot. 13-14. Moreover, Petitioner is wrong that Judge Pfaelzer held that
`
`DVB-S2 “does not satisfy the limitations of the ’710 patent.” Reply 14. Judge
`
`Pfaelzer only held that Hughes’s infringement of the ’032 patent involved a
`
`genuine dispute of material fact to be resolved by the jury. EX1067, *5.
`
`F.
`
`Exhibits that Petitioner does not rely on should be excluded
`
`Petitioner does not dispute it has not relied upon EXS1029-1031, 1035,
`
`1036, and 1038-1043. Opp. 14-15. Petitioner argues EXS1013, 1044, 1045, 1047-
`
`1049, 1055, 1059, and 1060 should be admitted to “maintain a complete record”
`
`(Opp. 15) but does not otherwise argue they are relevant. They should be excluded.
`
`
`
`-5-
`
`
`
`Cases IPR2017-00210
`Patents 7,116,710
`
`
`
`
`
`
`
`
`Date: March 26, 2018
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`
`
`/ Michael T. Rosato /
`Michael T. Rosato, Lead Counsel
`Reg. No. 52,182
`
`
`
`
`
`-6-
`
`
`
`Cases IPR2017-00210
`Patents 7,116,710
`
`
`CERTIFICATE OF SERVICE
`
`I certify that the foregoing Patent Owner’s Reply in Support of Motion to
`
`Exclude was served on this 26th day of March, 2018, on the Petitioner at the
`
`electronic service addresses of the Petitioner as follows:
`
`Richard Goldenberg
`Dominic Massa
`Michael H. Smith
`James M. Dowd
`Mark D. Selwyn
`Arthur Shum
`WILMER CUTLER PICKERING HALE AND DORR LLP
`richard.goldenberg@wilmerhale.com
`dominic.massa@wilmerhale.com
`michaelh.smith@wilmerhale.com
`james.dowd@wilmerhale.com
`mark.selwyn@wilmerhale.com
`arthur.shum@wilmerhale.com
`
`
`
`
`Date: March 26, 2018
`
`
`
`
`Respectfully submitted,
`
`
`/ Michael T. Rosato /
`Michael T. Rosato, Lead Counsel
`Reg. No. 52,182
`
`
`
`
`
`
`
`
`
`
`
`-7-
`
`